CrossBridge Bio co-founder and CEO Michael Torres. Photo via LinkedIn

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
The Cancer Prevention and Research Institute of Texas has awarded its latest round of grants. Photo via tmc.edu

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.
Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

TMC names 2025 cohort of cancer treatment innovators

ready to grow

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

  • Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
  • Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
  • Cynthia Hu and Zhiqiang An, both of UTHealth Houston
  • Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
  • Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
  • Eugene Sa & Minseok Kim, both of CTCELLS
  • Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
  • Dr. Hector Alila of Remunity Therapeutics
  • Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
  • João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
  • Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
  • Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
  • Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
  • Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
  • Robert Skiff and Norman Packard, both of 3582.ai
  • Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
  • Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
  • Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
  • Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics
The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.
CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

How Houston is emerging as a leader for oncology innovation, according to this expert

Houston innovators podcast episode 114

Houston is currently establishing itself as a hub for health care innovation — and Enrique Gomez should know. He's worked in the field of biopharmaceuticals across the continent.

As entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, he works with early stage startups and researchers. However, for decades he's worked in a much later stage of drug development, holding leadership positions at Takada in Latin America and Shire in Boston.

"Texas is very well recognized for cancer therapeutics," Gomez says on this week's episode of the Houston Innovators Podcast. "There's a lot of research going on. These researchers are looking at every angle — every possible strategy to tackle cancer."

At ACT, Gomez connects the startups or instigators with the resources they need to get their life-saving solutions to market. With cancer, there's not one thing that's going to work. There have to be options for treating cancer.

"Cancer is very heterogeneous. Not one strategy will be the single silver bullet to overcome the disease," Gomez says. "We are talking about personalized medicine. Every person is different and every cancer in every patient is different. It will require a number of approaches to overcome the health situation."

Thankfully, through TMC's ACT and the numerous research institutions working on the future of oncology, Houston's a great spot to move that needle.

"Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."

He shares more on how COVID-19 has affected drug development and research — as well as what's next for his own career — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Experts: Houston's VC ecosystem has set the foundation — now we need scale

guest column

Fervo Energy went public earlier this summer. The Houston geothermal company priced its IPO at $27 per share, raised $1.89 billion, and opened the next morning at a market capitalization north of $10 billion. By most measures, it is the largest venture-backed cleantech IPO in history and an unambiguous win for Houston. It’s also a useful moment to look at where Houston's venture ecosystem stands and where it can go. The highlight: Houston's venture ecosystem has real foundations and, with increased company formation activity, can grow into the scale our city's ambitions deserve.

A Houston energy story in the national recovery

The recent uptick in Houston venture activity follows national trends. U.S. venture deal count contracted roughly 22 percent from its 2021 peak through 2024 before rebounding to about 16,700 rounds in 2025. Houston's 23 percent increase in VC funding from 2023 to 2024 is part of a national recovery of comparable magnitude over the same time window.

The energy sector is where Houston exhibits unique trends—and where the story turns clearly positive. (Houston's strong health and space sectors deserve their own separate consideration.) By deal count, energy-related rounds have accounted for 15 to 20 percent of Houston activity, roughly consistent over the past few years.

By capital, energy's share surged from about 14 percent in 2023 to over 60 percent in 2025, driven by a small number of large Houston-headquartered rounds, primarily in geothermal and related technologies. Fervo is the obvious anchor, but Sage Geosystems, Quaise Energy, Zeta Energy, Vaulted Deep, Applied Carbon and Mariana Minerals have all closed meaningful rounds. Houston is concentrated and accelerating as an energy capital market, an invaluable position to build upon.

From foundation to scale

The institutional pieces are in place. Greentown Labs, Activate, the Ion and others have built sector-specialized infrastructure most cities would struggle to assemble. Fervo itself is an alum of both Activate and Greentown Labs. Mercury Fund closed its $160 million Fund V, its largest ever. Houston Angel Network, GOOSE Capital, Fathom Fund, and broader pre-seed and seed capital coverage are here. The Houston $10 million-plus Series A list now includes 40 rounds since 2021, which break roughly into two eras. While 2021 to 2022 was biotech-heavy, with companies like Sporos Bioventures, RadioMedix, Cellenkos and Coya Therapeutics, 2024 to 2025 has tilted clearly toward energy, climate, and critical minerals, with Vaulted Deep, Applied Carbon, Mariana Minerals, Sage Geosystems and Ignis H2 Energy among them.

What’s less developed is the volume of seed-stage companies flowing into that capital. Imagine a dozen more Fervos coming out of that infrastructure over the next decade, each generating jobs, recycled founder capital, and the next wave of operators and angel investors. That is the kind of opportunity Houston has within reach if we build the company-formation pipeline to feed it. To be relevant on the national stage as a venture market, and to drive an economy the size of Houston's into the 2030s, the city needs to be doing closer to 20 Series A rounds per month rather than per year. That throughput implies roughly 1,000 seed rounds per year, feeding the funnel at a 20 percent to 30 percent graduation rate. Reaching such throughput depends on how many new founders Houston produces and how quickly our innovation ecosystem can help them achieve lift-off.

Houston in context

The comparative picture brings the scaling challenge into focus. Between 2021 and 2024, Houston-area startups closed between 126 and 153 disclosed venture rounds per year, against a national count between 9,854 and 14,125. That places Houston at a little over 1 percent of the U.S. deal count. For comparison, Austin ran about three times Houston's deal count each year.

At the Series A level, Houston closed between 12 and 24 rounds in any given year. The median Houston Series A across the period was about $10.7 million, compared with $15.4 million in San Francisco. Houston founders are raising fewer and smaller Series A rounds than founders in peer metros, which points directly to where Houston has the most room to grow.

The unicorn picture tells the same story. From 2021 through 2025, the U.S. produced 590 venture-backed unicorns. Four were Houston-based: Solugen and Axiom Space in 2021, Cart.com in 2023, and Fervo Energy in 2024. Adding HighRadius from 2020 brings Houston's all-time total to five. Austin added 19 over the same five-year window. The path from here is to make Houston's entries on lists like these less the exception and more the rule.

Where this leads

Houston has a real opportunity to become the deepest, most credible energy and climate capital market in the country, with the company formation, talent and operator density to support it. The data shows the foundation is already in place. Fervo, Solugen and the growing roster of energy-adjacent Series A graduates are proof. Fervo's IPO is the first of what should be many. Houston has not had a venture-backed cleantech liquidity event of this scale before, and the city now has one to reference, recruit against and build on. With increased company formation at the seed and pre-seed stages, a Fervo-scale outcome need not be a generational event in Houston, but instead, it can become part of a chain reaction powering the city's economy.

---

Stephanie T. Schmidt, PhD, is the founder of a stealth startup, a Venture Fellow at Energy Transition Ventures, and an Executive MBA candidate at Rice University's Jones Graduate School of Business. Lawson Gow is the Chief Operating Officer of Greentown Labs. The full Houston VC landscape report is available at Energy Transition Ventures and CleanTech.Org.

Sources: Crunchbase, PitchBook-NVCA, Carta

8 can't-miss Houston business and innovation events for July

where to be

Editor's note: Summer is in full swing in Houston, but the city's innovation ecosystem isn't slowing down. This month brings AI workshops, energy and manufacturing discussions, entrepreneur-focused networking, and opportunities to connect with investors and industry leaders. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.

July 7 — How Oil and Gas Professionals are Building Wealth Smarter

Hear from oil and gas professionals on how to preserve wealth at this event put on by Financial Advice Center. The conversation will touch on topics like investing, taxes and retirement planning.

This event is Tuesday, July 7, from noon-1 p.m. at the Ion. Register here.

July 7 — What AI, Cybersecurity, and Tequila Have in Common.

Join Blue People and Alpfa Houston for this engaging presentation on the advantages and risks associated with AI at the latest installment of Tech + Tequila Talk. Cybersecurity veteran Reynaldo Gonzalez will lead the conversation.

This event is Tuesday, July 7, from 5-7 p.m. at the Ion. Register here.

July 7 — Speed to Market: Houston’s Advanced Manufacturing Edge

The Greater Houston Partnership presents a forum that explores what allows advanced manufacturing projects in Houston to move from concept to operation, where delays and bottlenecks occur, and more. Industry leaders Jennifer Clement from CliftonLarsonAllen LLP and Sarah Janes from San Jacinto College will lead the discussion.

This event is Tuesday, July 7, from 11:30 a.m.-1 p.m. at the Partnership Tower. Register here.

July 9 — Capital Connections Summit

Houston City College Center for Entrepreneurship will host the Capital Connections Summit this month, with a panel discussion focused on access to capital and technical assistance for small businesses and entrepreneurs. The event will be moderated by the U.S. Small Business Administration Houston District Office and will feature lenders, nonprofit microlenders, business advisors, and entrepreneurial support organizations. A live Q&A will follow the panel.

This event is Thursday, July 9, from 11 a.m.-1:30 p.m. at Houston City College Central Campus. Register here.

July 9 — Upstream: Digital Tech Meetup at Second Draught

Join Timbergrove at this month's gathering of energy, operations and technology professionals from across the upstream ecosystem. Discuss challenges, explore new ideas and network over pizza and beer at Second Draught.

This event is Thursday, July 9, from 5:30–8 p.m. at the Ion. Register here.

July 14 — Why Networking Isn’t Turning Into Deals, And What To Do Instead

Jada Powell, founder of Powell Consulting Group, will break down why networking often fails to convert into deals and what companies can do differently to turn conversations into qualified opportunities. Powell works with oil and gas, energy, and industrial companies on business development solutions. This session is part of the monthly Pipeline Series: How Oil & Gas Companies Actually Grow Revenue.

This event is Tuesday, July 14, from noon-1 p.m. at the Ion. Register here.

July 15 — From Pilot to Performance: Building Your AI Procurement Roadmap

It's not too late to join in on the GHP's two-part AI series on moving from experimentation to implementation. In session two, explore how procurement and supply chain leaders can scale AI responsibly to create long-term business value. This event will be led by Cassye Cook Provost, founder and principal of RossGrigsby Consultancy.

This virtual event is Wednesday, July 15, from 8:30-10 a.m. Register here.

July 30 — Rice University Summer Engineering Innovation Program - Demo Day 2026

Meet the young minds and see the final team project presentations from Rice University’s Summer Engineering Innovation Program. The 10-week program challenges Rice students to solve real-world challenges using AI, digital engineering, model-based systems engineering and Industry 4.0 technologies.

This event is Thursday, July 30, from 6-8 p.m. at the Ion. Find more information here.